These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 32340652)

  • 1. Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment.
    Onuma AE; Zhang H; Huang H; Williams TM; Noonan A; Tsung A
    Gene Expr; 2020 Jun; 20(1):53-65. PubMed ID: 32340652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy in Hepatocellular Carcinoma.
    Fulgenzi CAM; Talbot T; Murray SM; Silletta M; Vincenzi B; Cortellini A; Pinato DJ
    Curr Treat Options Oncol; 2021 Aug; 22(10):87. PubMed ID: 34424422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma.
    Ho WJ; Danilova L; Lim SJ; Verma R; Xavier S; Leatherman JM; Sztein MB; Fertig EJ; Wang H; Jaffee E; Yarchoan M
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?
    Ruiz de Porras V; Pardo JC; Notario L; Etxaniz O; Font A
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
    Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
    Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The next generation of immunotherapy: keeping lung cancer in check.
    Somasundaram A; Burns TF
    J Hematol Oncol; 2017 Apr; 10(1):87. PubMed ID: 28434399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma.
    Choi C; Yoo GS; Cho WK; Park HC
    World J Gastroenterol; 2019 May; 25(20):2416-2429. PubMed ID: 31171886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges.
    Chen Y; Gao M; Huang Z; Yu J; Meng X
    J Hematol Oncol; 2020 Jul; 13(1):105. PubMed ID: 32723363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma.
    Rizzo A; Brandi G
    Cancer Treat Res Commun; 2021; 27():100328. PubMed ID: 33549983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors?
    Rivera Vargas T; Apetoh L
    Front Immunol; 2019; 10():1181. PubMed ID: 31191545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoint inhibitors in HCC: Cellular, molecular and systemic data.
    Harkus U; Wankell M; Palamuthusingam P; McFarlane C; Hebbard L
    Semin Cancer Biol; 2022 Nov; 86(Pt 3):799-815. PubMed ID: 35065242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives.
    Mocan T; Sparchez Z; Craciun R; Bora CN; Leucuta DC
    Clin Transl Oncol; 2019 Jun; 21(6):702-712. PubMed ID: 30387047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma.
    Cheng AL; Hsu C; Chan SL; Choo SP; Kudo M
    J Hepatol; 2020 Feb; 72(2):307-319. PubMed ID: 31954494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Favorable response to second-line atezolizumab and bevacizumab following progression on nivolumab in advanced hepatocellular carcinoma: A case report demonstrating that anti-VEGF therapy overcomes resistance to checkpoint inhibition.
    Swed B; Ryan K; Gandarilla O; Shah MA; Brar G
    Medicine (Baltimore); 2021 Jun; 100(25):e26471. PubMed ID: 34160456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Influence of Immune Heterogeneity on the Effectiveness of Immune Checkpoint Inhibitors in Multifocal Hepatocellular Carcinomas.
    Huang M; He M; Guo Y; Li H; Shen S; Xie Y; Li X; Xiao H; Fang L; Li D; Peng B; Liang L; Yu J; Kuang M; Xu L; Peng S
    Clin Cancer Res; 2020 Sep; 26(18):4947-4957. PubMed ID: 32527942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma.
    Dal Bo M; De Mattia E; Baboci L; Mezzalira S; Cecchin E; Assaraf YG; Toffoli G
    Drug Resist Updat; 2020 Jul; 51():100702. PubMed ID: 32371296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune checkpoint blockade in advanced hepatocellular carcinoma: an update and critical review of ongoing clinical trials.
    Harding JJ
    Future Oncol; 2018 Sep; 14(22):2293-2302. PubMed ID: 29663837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
    Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H
    Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of tumor-associated regulatory T cell deletion and PD-1/PD-L1 blockade: A promising immunotherapy for hepatocellular carcinoma?
    Yang HY; Sun LJ; Mao YL
    Hepatobiliary Pancreat Dis Int; 2018 Apr; 17(2):93-94. PubMed ID: 29576280
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunotherapy for hepatocellular carcinoma.
    Zongyi Y; Xiaowu L
    Cancer Lett; 2020 Feb; 470():8-17. PubMed ID: 31811905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.